Research
Hormonal
GLP-1 receptor agonists provide cardiovascular benefits for patients with obesity, even those without diabetes, by reducing the risk of major adverse cardiovascular events.
GLP-1 medications like Semaglutide (2.4 mg weekly) have been shown to reduce the risk of heart attacks, strokes, and cardiovascular death in people with obesity, even if they don't have diabetes. This is a significant benefit beyond weight loss. However, these drugs are expensive and require long-term use.
StrongSupportsVERY_HIGH confidence
结果显示，每周注射一次2.4 mg司美格鲁肽可使成年超重或肥胖人群的主要不良心血管事件(心血管死亡、非致死性心肌梗死，非致死性卒中)风险降低20%。
Why this rating
Based on the SELECT study, a large, randomized, double-blind, placebo-controlled trial.
Source
The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Jun Yin et al. · Chinese Science Bulletin (Chinese Version) · 2024
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →